Otsuka agreed to acquire Transcend Therapeutics in a deal valued at roughly $1.2 billion, including a $700 million upfront payment, to expand its neuropsychiatric drug portfolio. The target is centered on TSND-201 (methylone), a therapy designed to rapidly restore “neuroplasticity,” with clinical development for post-traumatic stress disorder now moving toward Phase 3 recruitment in the U.S. Transcend’s approach is positioned as neuroplasticity-focused rather than receptor-mediated through the serotonin receptor cited as associated with hallucinogenic risk in prior MDMA-related programs. The deal adds a large-company balance sheet and commercialization reach for a candidate already tied to peer-reviewed mid-stage results published in JAMA Psychiatry. Otsuka framed the acquisition as a potential paradigm shift for a space where PTSD treatment options remain limited, and it expects deal completion between April and end of June subject to customary conditions.